Quick Answer
Tyra Biosciences, Inc. reported R&D Expense of $102.93 million for fiscal year 2025.
Tyra Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $102.93M | +28.5% |
| 2024 | $80.08M | +28.1% |
| 2023 | $62.52M | +45.4% |
| 2022 | $43.01M | +108.4% |
| 2021 | $20.64M | +186.5% |
| 2020 | $7.20M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.47M | +12.2% | +4.8% |
| June 30, 2025 | $24.31M | +35.1% | -2.6% |
| March 31, 2025 | $24.96M | +45.1% | +10.0% |
| September 30, 2024 | $22.70M | +17.8% | +26.1% |
| June 30, 2024 | $18.00M | +48.0% | +4.6% |
| March 31, 2024 | $17.20M | +65.3% | -10.7% |
| September 30, 2023 | $19.27M | +76.6% | +58.5% |
| June 30, 2023 | $12.16M | +1.0% | +16.9% |
- Tyra Biosciences, Inc. showed an increase of +28.5% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Tyra Biosciences, Inc.’s r&d expense has grown by 1329.0% (from $7.20 million to $102.93 million).
- The most recent figure is from Tyra Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: